Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$3.25 USD

3.25
340,854

+0.03 (0.93%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $3.26 +0.01 (0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Biogen (BIIB) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

by Zacks Equity Research

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PBYI vs. GMAB: Which Stock Is the Better Value Option?

Zacks Equity Research

Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort

by Zacks Equity Research

Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.

Zacks Equity Research

Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

by Zacks Equity Research

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Zacks Equity Research

Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.

Zacks Equity Research

Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.

Zacks Equity Research

Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Zacks Equity Research

bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.

Zacks Equity Research

Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.

Zacks Equity Research

Bausch (BHC) Q3 Earnings & Sales Miss, Guidance Lowered

by Zacks Equity Research

Bausch (BHC) Q3 earnings and sales decline year over year due to the unfavorable impact of foreign exchange rates. The company also lowers its annual guidance.

Zacks Equity Research

Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.

Zacks Equity Research

Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Zacks Equity Research

Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Zacks Equity Research

Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up

by Zacks Equity Research

Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.

Zacks Equity Research

Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 90.91% and 11.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.

Zacks Equity Research

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

by Zacks Equity Research

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Zacks Equity Research

Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised

by Zacks Equity Research

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Zacks Equity Research

Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised

by Zacks Equity Research

Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.

Zacks Equity Research

Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.

Zacks Equity Research

Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y

by Zacks Equity Research

Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.

Zacks Equity Research

Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.